Acne Drugs Market (2026 - 2033)

Acne Drugs Market Summary

The global acne drugs market size was valued at USD 10.2 billion in 2025 and is projected to grow from USD 10.8 billion in 2026 to USD 15.9 billion in 2033, at a CAGR of 5.7% from 2026 to 2033. The North America market dominated with a revenue share of approximately 40.0% in 2025. The market for acne drugs is experiencing steady growth due to the rising prevalence of acne across age groups, increasing awareness of dermatological health, and growing demand for effective treatment options for inflammatory and non-inflammatory acne. The market is experiencing continuous innovation in topical therapies, oral medications, biologics, and advanced dermatology solutions as pharmaceutical companies focus on improving treatment efficacy, reducing side effects, and addressing unmet needs among acne patients.

Acne is a chronic skin condition influenced by hormonal fluctuations, unhealthy lifestyle choices, and dietary changes. In March 2024, Pierre Fabre Laboratories announced the publication of the first global epidemiological study on acne in the Journal of the American Academy of Dermatology (JAAD). This study analyzed data from over 50,000 adults across 20 countries and highlighted the prevalence of acne among different age groups and regions. It emphasized the ongoing need for effective acne management solutions and the increasing global demand for acne medications and dermatological treatments.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Various lifestyle factors contribute to acne, such as smoking, rising stress levels, hormonal imbalances, and exposure to excessive pollution. For example, a review published in the International Journal of Molecular Sciences in September 2024 examined the impact of particulate matter (PM) pollution on skin health. The review reported that pollutants can penetrate the skin, triggering oxidative stress, inflammation, and disruption of the skin barrier. It emphasized that increased exposure to urban pollution can exacerbate various skin conditions and accelerate skin damage. This underscores the growing demand for dermatological treatments, including acne therapies, as consumers seek solutions to skin concerns related to pollution.

Analyst Perspective

The acne drugs market is evolving as consumers increasingly seek treatments that balance effectiveness with safety and long-term skin health. While demand remains strong for both prescription and over-the-counter products, purchasing decisions are increasingly influenced by product tolerability, convenience, and visible results. Companies with strong dermatology expertise, established healthcare relationships, and broad product portfolios are likely to strengthen their market position. The market is also seeing growing interest in combination therapies and personalized treatment approaches that address different skin types and severity levels. In the coming years, competitive advantage will depend on clinical effectiveness, brand trust, and the ability to meet rising consumer expectations for safer and more targeted skincare solutions.

Type Insights

Inflammatory acne dominated the market, accounting for over 60.0% of the market share in 2025. The factors contributing to the segment growth include bacterial skin infections that can cause inflammatory acne. For instance, in February 2026, Arctic Therapeutics announced the enrollment of the first patients in a Phase IIa clinical trial evaluating AT-004, a topical therapy for acne vulgaris. The investigational treatment targets the anti-inflammatory pathway associated with inflammatory skin conditions, including acne. This development highlights ongoing research into advanced therapies to address inflammation-driven acne and improve treatment options for patients with moderate-to-severe inflammatory acne. In addition, inflammatory acne caused by bacterial infections may lead to cysts that require medical attention. The increasing number of treatment options for inflammatory acne, such as topical creams, oral drugs, and extraction procedures, is also contributing to segment growth.

The non-inflammatory acne segment is expected to grow significantly over the forecast period. Comedonal acne, also known as non-inflammatory acne, is caused by excess oil secretion in the skin. The increasing awareness of availability of various treatment options for non-inflammatory acne, such as salicylic acid, tea tree oil, benzoyl peroxide, glycolic acid, and retinoids such as tretinoin and isotretinoin, are expected to boost segment growth.

Therapeutic Class Insights

Over-the-counter (OTC) drugs dominated the market, accounting for around 35.0% in 2025. The expensive alternatives and growing consumer awareness are driving segment growth. Nonprescription drugs for treating acne are on the rise due to greater self-awareness, accurate dosing, ease of administration, and user-friendliness for end consumers. Various companies offer over-the-counter acne treatments, including Johnson & Johnson Services, Inc., Pfizer Inc., and GALDERMA.

The topical retinoids segment is expected to register the fastest CAGR over the forecast period. The rising prevalence of acne is primarily driving growth in the segment. Topical retinoids are used to treat many skin conditions, including acne, and are available as creams, serums, and gels in various concentrations, with user-friendly packaging. Companies are developing innovative solutions to treat skin conditions. For instance, in August 2025, Alembic Pharmaceuticals received U.S. FDA approval for its Tretinoin Cream USP 0.025%, a topical retinoid indicated for the treatment of acne vulgaris. Tretinoin is a widely used retinoid that helps regulate skin cell turnover and reduce acne lesions, and the approval expanded access to a proven topical therapy option for acne patients. This development reflects continued innovation and competition in the topical retinoids segment, supporting market growth through the introduction of effective and accessible acne treatments.

Mode of Administration Insights

The topical segment dominated the market, accounting for over 45.0% in 2025, owing to rising demand for topical products due to their ease of use, precise dosing, and high availability as over-the-counter drugs. Topical medications are used to treat mild to moderate acne, and various companies offer them as nonprescription drugs. For instance, in May 2026, Galderma received U.S. FDA approval to switch Differin Epiduo Acne Gel from prescription-only to over-the-counter use for individuals aged 12 years and older. The combination topical therapy targets multiple causes of acne by combining a retinoid with an antibacterial ingredient, improving accessibility to clinically proven topical acne treatment options. Such developments in the market drive growth in this segment.

The injectable segment is expected to register the fastest CAGR over the forecast period. Mild acne can be treated with topical drugs, but severe acne, nodular, and cystic acne can be treated by injecting a steroid drug, enabling faster recovery and reduction in pain. In addition, cortisone is injected because it penetrates deeply into the skin, making it an effective alternative to topical treatments for treating cystic acne and preventing scars. Such advanced alternatives and their increased demand drive the segment growth.

Distribution Channel Insights

Retail pharmacies dominated the market, accounting for more than 35.0% of the market in 2025. Increased skin awareness, ready-to-use drugs available in customized concentrations for various affected individuals, and their nonprescription availability are driving growth in the segment. Over-the-counter medicines available at retail pharmacies and increased consumer awareness of acne drugs drive segment growth. Retail pharmacies offering acne drugs include CVS Pharmacy, Walmart, Walgreens, and The Kroger Co., to name a few. Such key players are expected to drive the segment growth.

Online pharmacies are expected to register the fastest CAGR during the forecast period. Increased internet connectivity and rising consumer awareness of skin issues are driving the segment growth. The growing telemedicine sector has paved the way for online pharmacies, enabling them to offer a wide range of medications for treating various health issues, such as acne. Some key players expected to drive the segment growth are Patel's Chemist Limited's Click2Pharmacy, PharmEasy, Tata 1mg, and Expert Health Limited's LloydsPharmacy.

Regional Insights

North America acne drugs industry dominated the global market in 2025 with a revenue share of around 40.0%, attributed to the rising prevalence of acne, the developed healthcare infrastructure, and the strong presence of companies in the market. According to the Canadian Dermatology Association, 5.6 million citizens are affected by acne, accounting for around 20% of the population. Various companies are offering innovative solutions. For instance, in April 2025, Bausch Health’s CABTREO became available in the U.S. market following its FDA approval for the treatment of acne vulgaris in patients aged 12 years and older. Such developments are expected to drive market growth.

To learn more about this report, Download Free Sample Report

U.S. Acne Drugs Market Trends

The U.S. acne drugs industry accounted for a significant share of the global market in 2025. The increasing incidence of acne and the presence of established pharmaceutical firms are primarily driving market growth. According to data from Pfizer Inc., acne is a common skin condition in the U.S. and affects 50 million citizens annually. Various companies are engaged in R&D to develop advanced alternatives for treating chronic conditions.

Europe Acne Drugs Market Trends

Europe acne drugs industry accounted for a significant share of the market in 2025. The altered lifestyle, rise in stress levels, and hormonal imbalances are the main factors causing acne and driving high demand for its treatment. Companies are forming partnerships to offer acne solutions to affected citizens. For instance, in November 2025, Cosmo Pharmaceuticals and Glenmark Pharmaceuticals received marketing authorization from the European Commission for Winlevi cream to treat acne vulgaris in multiple European countries. The topical therapy is approved for adults and adolescents aged 12 years and above and represents a new treatment approach targeting androgen-related pathways involved in acne development. The approval and planned commercialization across European markets highlight continued innovation and collaboration among dermatology companies to address the high burden of acne and expand treatment options in the region.

Acne is a very common skin condition in the UK. Several companies are developing new drugs to treat the condition. For instance, in February 2024, Cutera launched AviClear, an energy-based device for long-term acne treatment, in the UK, Europe, and Australia. Such innovations are expected to drive market growth.

Asia Pacific Acne Drugs Market Trends

The Asia Pacific acne drugs industry is estimated to register the fastest CAGR over the forecast period. According to the SingHealth Group, about 88% of adolescents have mild to moderate acne. For instance, in August 2025, a research study published in Clinical, Cosmetic and Investigational Dermatology evaluated the role of immune-related factors in the development of acne vulgaris, highlighting the inflammatory mechanisms involved in acne progression. The study emphasized that acne is a complex inflammatory skin disorder involving immune responses and biological pathways, supporting the continued need for advanced acne treatment approaches, including topical therapies and targeted drug development. Such research advancements are encouraging pharmaceutical companies to explore improved treatment options for acne patients across Asia Pacific and other regions, particularly in India, where acne is highly prevalent.

Key Acne Drugs Company Insights

Some key companies in the market include GALDERMA, Johnson & Johnson Services, Inc., GSK Plc., Sun Pharmaceutical Industries Ltd., and Bayer AG, among others. Key companies are involved in strategic initiatives such as innovating new products, collaborating with institutions and other industries, and establishing partnerships.

Key Acne Drugs Companies

The following key companies have been profiled for this study on the acne drugs market:

• GALDERMA

• Johnson & Johnson Services, Inc.

• GSK Plc.

• Pfizer Inc.

• AbbVie Inc.

• Sun Pharmaceutical Industries Ltd.

• Bausch Health Companies Inc.

• Nestlé Skin Health S.A.

• Bayer AG

• Viatris Inc.

• Teva Pharmaceutical Industries Ltd.

• F. Hoffmann-La Roche Ltd

• LEO Pharma A/S

• Perrigo Company plc

Recent Developments

• In October 2025, Cosmo Pharmaceuticals announced that South Korea’s Ministry of Food and Drug Safety (MFDS) approved Winlevi cream for the treatment of acne vulgaris in patients aged 12 years and older. Winlevi is a novel topical acne therapy that acts by inhibiting the androgen receptor in sebaceous glands to reduce sebum production and inflammation. The approval expands access to advanced acne treatments in the Asia Pacific region, where rising acne prevalence and growing dermatology awareness are driving demand for innovative solutions.

• In July 2025, Galderma reported strong growth in its Therapeutic Dermatology portfolio, driven by continued expansion of its dermatology treatment offerings and innovation pipeline. The company highlighted ongoing investments in dermatology solutions, reflecting the increasing focus of pharmaceutical companies on developing advanced therapies for chronic skin conditions, including acne and other inflammatory dermatological disorders.

Acne Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global acne drugs market report based on type, therapeutic class, mode of administration, distribution channel, and region .

• Type Outlook ( Revenue, USD Billion, 2021 - 2033)

  • Inflammatory Acne

  • Non-inflammatory Acne

• Therapeutic Class Outlook ( Revenue, USD Billion, 2021 - 2033)

  • Topical Retinoids

  • Oral Antibiotics

  • Oral Retinoids

  • Over-the-Counter (OTC) Drugs

• Mode of Administration Outlook ( Revenue, USD Billion, 2021 - 2033)

  • Topical

  • Oral

  • Injectable

• Distribution Channel Outlook ( Revenue, USD Billion, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others

• Regional Outlook ( Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

  • Middle East and Africa (MEA)

    • KSA

    • UAE

    • South Africa